PRAGUE, Czechia—In patients with an ejection fraction > 40% recovering from a worsening heart failure (HF) event, sacubitril/valsartan (Entresto; Novartis) led to greater reductions in NT-proBNP ...
Please provide your email address to receive an email when new articles are posted on . In women with suspected ischemia, those with a high left ventricular ejection fraction have reduced risk for ...
ENTRESTO The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial. The Food and Drug Administration has ...
Patients with heart failure (HF) who are started on sacubitril-valsartan (Entresto) in the hospital or soon after discharge will see a sharp drop in clinical risk whether their ejection fraction is ...
May 18, 2007 (Denver, CO) - A prospective trial has demonstrated that two novel Holter-based markers could help identify patients with normal LVEFs after an acute MI who have an increased mortality ...
Please provide your email address to receive an email when new articles are posted on . Sacubitril/valsartan showed benefit across the spectrum of left ventricular ejection fraction in stable patients ...
A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actions—A SONAR Report The median age was 71 years, and 54% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback